Skip to main content
SpringerLink
Log in

Novel Developments in AML – ASH 2010

  • ASH Report
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Acute myeloid leukaemia (AML) is a life-threatening stem cell disorder characterized by rapid and uncontrolled proliferation and accumulation of myeloblasts. Its prognosis and clinical picture vary depending on the genes that underwent deregulation, the cell type involved and the specific biological properties of the clone. If treated appropriately, the rate of complete remission (CR) is rather high (between 60 and 80%). By contrast, however, long-term relapse-free survival is poor in these patients (10–30% at 5 years). Thus, there are ongoing attempts to improve the therapy of AML patients by the introduction of novel treatment strategies and novel therapeutics. At the ASH-meeting 2010 a total number of 872 abstracts on AML were presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Breems DA, Van Putten WJL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol, 29(26): 4791–4797, 2010

    Google Scholar 

  • Al-Khabori MK, Yee K, Gupta V, et al. Validation of monosomal karyotype based model in the risk stratification of acute myeloid leukemia. Blood, 116(21): 1132, 2010 (abstr 2745)

    Google Scholar 

  • Pogosova-Agadjanyan EL, Kopecky KJ, Lee H, et al. Over-expression of novel IRF8 splice variants is associated with a significant decrease in relapse-free survival in adult AML patients. Blood, 116(21): 1679, 2010 (abstr 1679)

    Google Scholar 

  • Wierzbowska A, Pluta A, Stepka K, et al. The prognostic role of jagged-1 protein expression in acute myeloid leukemia patients. Blood, 116(21): 1124, 2010 (abstr 2726)

    Google Scholar 

  • Mikhail R, Chien S, Othus M, et al. CD38 status of CD34+myeloblasts, but not side population (SP) frequency, predicts initial response to induction therapy in patients with newly diagnosed Acute Myeloid Leukemia (AML). Blood, 116(21): 463, 2010 (abstr 1056)

    Google Scholar 

  • Roug AS, Nolta JA, Oestergaard Larsen H, et al. Flow cytometric detection of minimal residual disease in acute myeloid leukemia – the addition of hMICL and CD123 Add to sensitivity and applicability. Blood, 116(21): 1120, 2010 (abstr 2719)

    Google Scholar 

  • Tong C, Yang J, Lin Y, et al. Predictable recurrence by regular monitoring minimal residual disease with flowcytometry in the patients with both AML and ALL: a single-center study of 158 cases. Blood, 116(21): 1661, 2010 (abstr 1661)

    Google Scholar 

  • Sauter T, Ringel K, Braess J, et al. Minimal residual disease assessment by flow cytometry in AML patients at Time of aplasia post-induction is highly predictive of outcome and strongly correlates with molecular MRD in a subgroup of NPM1 positive patients. Blood, 116(21): 1723, 2010 (abstr 1723)

    Google Scholar 

  • Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med, 361(13): 1249–1259, 2009

    Article  PubMed  CAS  Google Scholar 

  • Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med, 361(13): 1235–1248, 2009

    Article  PubMed  Google Scholar 

  • Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol, 28(5): 808–814, 2010

    Article  PubMed  CAS  Google Scholar 

  • Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 102(7): 2379–2386, 2003

    Article  PubMed  CAS  Google Scholar 

  • Naqvi K, Ravandi F, Kantarjian H, et al. Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 116(21): 464, 2010 (abstr 1061)

    Google Scholar 

  • Faderl S, Ravandi F, Garcia-Manero G, et al. Frontline therapy for older patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine plus low-dose cytarabine induction followed by prolonged consolidation with clofarabine plus low-dose cytarabine alternating with decitabine. Blood, 116(21): 152, 2010 (abstr 336)

    Google Scholar 

  • Attar EC, Donohue KA, Amrein PC, et al. Phase II Study of Bortezomib added to standard daunorubicin and cytarabine induction and dose escalation of bortezomib with intermediate-dose cytarabine consolidation therapy for patients with previously untreated acute myeloid leukemia age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502. Blood, 116(21): 150, 2010 (abstr 331)

    Google Scholar 

  • Blum W, Klisovic RB, Garzon R, et al. Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML). Blood, 116(21): 3292, 2010 (abstr 3293)

    Google Scholar 

  • Sekeres MA, Gundacker H, Lancet J, et al. A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). Blood, 116(21): 150, 2010 (abstr 332)

    Google Scholar 

  • Ades L, Prebet T, Stamatoullas A, et al. Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM). Blood, 116(21): 225, 2010 (abstr 508)

    Google Scholar 

  • Itzykson R, Thepot S, Beyne-Rauzy O, et al. Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). Blood, 116(21): 901, 2010 (abstr 2183)

    Google Scholar 

  • Brunnberg U, Mohr M, Noppeney R, et al. Induction therapy by Ara-C plus daunorubicin versus Ara-C plus gemtuzumab ozogamicin: interim analysis of a randomized phase II trial of the SAL in elderly patients with acute myeloid leukemia. Blood, 116(21): 152, 2010 (abstr 335)

    Google Scholar 

  • Burnett A, Hills R, Hunter AE, et al. The addition of gemtuzumab ozogamicin to low dose Ara-C improves remission rates but not survival: results of the UK LRF AML14 and NCRI AML16 "Pick a Winner" Comparison. Blood, 116(21): 13, 2010 (abstr 18)

    Google Scholar 

  • Aigner M, Feulner J, Kischel R, et al. Autologous T cells from AML patients can be effectively recruited for in-vitro lysis of blasts by a novel CD33/CD3-bispecific BiTE antibody. Blood, 116(21): 12, 2010 (abstr 14)

    Google Scholar 

  • Konopleva M, Hogge DE, Rizzieri DA, et al. Phase I trial results for SL-401, a novel Cancer Stem Cell (CSC) targeting agent, demonstrate clinical efficacy at tolerable doses in patients with heavily pre-treated AML, poor risk elderly AML, and high risk MDS. Blood, 116(21): 1513, 2010 (abstr 3298)

    Google Scholar 

  • Gotlib JR, DeAngelo DJ, George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood, 116(21): 144, 2010 (abstr 316)

    Google Scholar 

  • Berneman ZN, Van de Velde A, Anguille S, et al. WT1-targeted dendritic cell vaccination as a post-remission treatment to prevent full relapse in acute myeloid leukemia. Blood, 116(21): 12, 2010 (abstr 16)

    Google Scholar 

  • Sugiyama H, Tsuboi A, Oka Y, et al. Long-term WT1 peptide vaccination over 7 years for 3 AML patients with molecular relapse. Blood, 116(21): 1349, 2010 (abstr 3294)

    Google Scholar 

  • Ades L, Raffoux L, Chevret S, et al. Is AraC required in the treatment of standard risk APL? Long term results of a randomized trial (APL 2000) from the French Belgian Swiss APL Group. Blood, 116(21): 11, 2010 (abstr 13)

    Google Scholar 

  • Lengfelder E, Lo-Coco F, Montesinos P, et al. Treatment of molecular and clinical relapse of Acute Promyelocytic Leukemia (APL) with arsenic trioxide: results of the European Registry of Relapsed APL. Blood, 116(21): 12, 2010 (abstr 15)

    Google Scholar 

  • Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. New cases of acute promyelocytic leukemia treatment by arsenic trioxide alone and their long term follow up. Blood, 116(21): 224, 2010 (abstr 506)

    Google Scholar 

  • Leblebjian H, McDonnell A, Skirvin JA, et al. Predictive factors for all-trans retinoic acid related differentiation syndrome in acute promyelocytic leukemia. Blood, 116(21): 462, 2010 (abstr 1052)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

    W. R. Sperr & P. Valent

Authors
  1. W. R. Sperr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Valent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. R. Sperr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sperr, W., Valent, P. Novel Developments in AML – ASH 2010. memo 4, 106–109 (2011). https://doi.org/10.1007/s12254-011-0259-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-011-0259-2

Keywords

Search

Navigation